Company Overview of HemoShear, LLC
HemoShear, LLC, a biotechnology research company, develops and creates human-relevant systems that replicate the biology of organ systems and diseases in drug discovery and development. It conducts various experimental programs using human or animal primary cells; recreates in vivo hemodynamic conditions; cultures multiple cell types together to restore native biology; uses primary cells in physiologically accurate media conditions; creates physiologically relevant systems for understanding human responses in healthy and disease states; and provides human vascular systems, including artery systems, arteriole and microvascular systems, advanced inflammatory systems, atherosclerosis-prone cond...
1115 5th Street SW
Charlottesville, VA 22902
Founded in 2008
Key Executives for HemoShear, LLC
Chairman and Chief Executive Officer
Vice President of Operations
Compensation as of Fiscal Year 2014.
HemoShear, LLC Key Developments
HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014
Jun 17 14
HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014. Venue: San Diego Convention Center, San Diego, California, United States. Presentation Date & Speakers: Jun-24-2014, Vincent Aurentz, Chief Business Officer. Jun-25-2014, Brian R. Wamhoff, Co-Founder, Vice President of Research & Development and Director.
HemoShear, LLC Enters into R&D Collaboration with Medivir AB
Apr 23 14
HemoShear, LLC announced research collaboration with Medivir AB. The collaboration will explore the application of HemoShear's platform in an undisclosed area of strategic interest. In this initial phase of the collaboration, HemoShear will characterize biological mechanisms and the effects of drug candidates on liver tissue using the Company's first-in-class human liver system. The HemoShear human liver system accurately replicates in vivo physiological conditions, enabling a more precise and definitive assessment of targets and drug candidates, drug-induced changes in biology and pharmacological responses. The collaboration with Medivir will also leverage and contribute to the set of drug exposure data HemoShear is creating as part of an ongoing program funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of NIH.
HemoShear, LLC to Develop Human Cancer Models to Improve Industry Success Rates in New Anticancer Drug Development
Nov 7 13
Small Business Innovation Research contract awarded to HemoShear, LLC by the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH). HemoShear's contract with the National Cancer Institute will support the development of human cell-based systems that accurately replicate the biology of lung and pancreatic tumors, two of the deadliest groups of tumors. HemoShear's success in this initial stage of tumor system development will lead to development of other cancer tumor systems, to systems that replicate metastasis and potentially to new treatments for patient-specific tumors.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 7, 2014
October 20, 2013